GlassScriptPhysician profile
Angela Sinon
NPI 1427586239
$2,196.08
in general payments reported to CMS, 2019-2025
21 companies · $961 in 2025
The $961 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $931 · 2023: $47.43 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $337.12 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $320.56 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $280.24 | 2021-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $203.59 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $194.82 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $176.59 | 2022 | |
| Lilly USA, LLC | $172.51 | 2021-2025 | Jardiance, Kisunla, Mounjaro |
| Exact Sciences Corporation | $91.11 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.27 | 2021-2025 | |
| Mimedx Group, INC. | $46.78 | 2025 | |
| Alkermes, INC. | $40.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.61 | 2022 | |
| Glaxosmithkline, LLC. | $25.49 | 2023 | Arexvy, Shingrix, Bexsero |
| Lundbeck LLC | $22.34 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.74 | 2022 | |
| Axsome Therapeutics, INC. | $19.47 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $19.42 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.13 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $15.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Sinon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.